

Ref: FOI/GS/ID 4537

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone
Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net

1 March 2018

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Ovarian and Prostate treatments.

You asked:

1 – *How many Ovarian Carcinoma patients (any stage) have been diagnosed in the last 12 months?*

2 – *How many stage III or IV Ovarian Carcinoma patients have received Chemotherapy for the first time in the last 12 months?*

Of these how many patients are on Platinum based therapy (Monotherapy or combination therapy)?

3 – *How many stage III or IV Ovarian Carcinoma patients have been diagnosed as Platinum refractory (i.e. progression of disease whilst receiving Platinum therapy) or resistant (i.e. progression of disease within 6 months of last Platinum dose) in the last 12 months?*

4 – *How many patients with Stage III or IV Ovarian Carcinoma have been treated with the following treatments in the last 12 months?*

5 – *Within your Trust how many patients with Advanced Prostate Cancer have been treated in the past 12 months with the following treatments?*

6 – *How many patients being treated with Abiraterone or Enzalutamide and have been on this treatment for more than 1 year?*

Trust response:

1 – 87

2 – 12 Of these how many patients are on Platinum based therapy (Monotherapy or combination therapy)? 10

3 – Unable to answer

4 –

Treatments	Stage III or IV patients (total number)	Number of Stage III or IV Platinum refractory OR Platinum resistant

		patients
Total Patients	27	Unable to answer
PEG Liposomal Doxorubicin (Caelyx)	5	Unable to answer
Gemcitabine	0	Unable to answer
Paclitaxel	16	Unable to answer
Docetaxel	0	Unable to answer
Bevacizumab	9	Unable to answer
Topotecan	0	Unable to answer
Clinical trial therapy	0	Unable to answer
Other – please specify	Caroboplatin - 4	Unable to answer

5 –

Treatment	Patients
Abiraterone (Zytiga)	22
Cabazitaxel (Jevtana)	2
Docetaxel (Taxotere)	26
Enzalutamide (Xtandi)	14
Radium-223 (Xofigo)	42

6 –

41
